D. Boral Capital Reaffirms Buy Rating for Tevogen Bio (NASDAQ:TVGN)

D. Boral Capital restated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a research report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Tevogen Bio Stock Performance

NASDAQ TVGN opened at $1.27 on Tuesday. The business has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.20. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $3.09.

Insiders Place Their Bets

In other Tevogen Bio news, CEO Ryan H. Saadi sold 1,438,206 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the transaction, the chief executive officer now directly owns 116,814,453 shares in the company, valued at approximately $143,681,777.19. This represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 73.24% of the company’s stock.

Institutional Trading of Tevogen Bio

Several hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after buying an additional 16,695 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Tevogen Bio by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after buying an additional 107,566 shares during the period. Barclays PLC lifted its holdings in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after buying an additional 12,847 shares in the last quarter. XTX Topco Ltd bought a new stake in Tevogen Bio during the fourth quarter valued at $55,000. Finally, Northern Trust Corp lifted its position in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after purchasing an additional 13,595 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.